(SBRA) Sabra Healthcare REIT - Overview
Stock: Skilled Nursing, Senior Housing, Behavioral Health, Specialty Hospitals, Loans
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 6.74% |
| Yield on Cost 5y | 9.77% |
| Yield CAGR 5y | 0.00% |
| Payout Consistency | 93.0% |
| Payout Ratio | 2.0% |
| Risk 5d forecast | |
|---|---|
| Volatility | 22.0% |
| Relative Tail Risk | 2.24% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.87 |
| Alpha | 16.57 |
| Character TTM | |
|---|---|
| Beta | 0.086 |
| Beta Downside | -0.012 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.22% |
| CAGR/Max DD | 0.94 |
Description: SBRA Sabra Healthcare REIT January 10, 2026
As of September 30 2025, Sabra Healthcare REIT’s investment portfolio comprised 363 real-estate properties, totaling 36,998 beds/units across the United States and Canada. The assets break down into 217 skilled-nursing and transitional-care facilities, 32 senior-housing communities owned and leased, 83 senior-housing communities managed under third-party agreements, 16 behavioral-health facilities, and 15 specialty hospitals or related properties.
In addition to the property holdings, Sabra reported 14 loan-receivable investments (three mortgages and 11 other loans), four preferred-equity stakes, and two interests in unconsolidated joint ventures, reflecting a diversified income mix beyond pure real-estate rent.
Key sector drivers that influence Sabra’s outlook include: (1) the U.S. population aged 65+ is projected to rise from 56 million in 2023 to roughly 78 million by 2035, expanding demand for senior-care beds; (2) Medicare and Medicaid reimbursement trends remain a primary revenue lever-recent CMS policy updates have modestly increased per-stay rates for skilled-nursing services, supporting cash-flow stability; and (3) REIT-level metrics show the health-care REIT average occupancy hovering around 86 % with a weighted-average cap rate near 5.5 % in 2024, providing a benchmark for Sabra’s performance.
For a deeper, data-driven look at how Sabra’s portfolio metrics compare to industry baselines, the ValueRay platform offers granular analytics that can help you assess the REIT’s risk-adjusted upside.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 175.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.37 > 1.0 |
| NWC/Revenue: 26.40% < 20% (prev 9.88%; Δ 16.52% < -1%) |
| CFO/TA 0.06 > 3% & CFO 341.2m > Net Income 175.1m |
| Net Debt (2.41b) to EBITDA (474.0m): 5.09 < 3 |
| Current Ratio: 2.59 > 1.5 & < 3 |
| Outstanding Shares: last quarter (243.6m) vs 12m ago 2.75% < -2% |
| Gross Margin: 66.38% > 18% (prev 0.68%; Δ 6569 % > 0.5%) |
| Asset Turnover: 13.63% > 50% (prev 12.75%; Δ 0.88% > 0%) |
| Interest Coverage Ratio: 2.65 > 6 (EBITDA TTM 474.0m / Interest Expense TTM 111.6m) |
Altman Z'' -1.31
| A: 0.04 (Total Current Assets 320.7m - Total Current Liabilities 124.0m) / Total Assets 5.56b |
| B: -0.35 (Retained Earnings -1.96b / Total Assets 5.56b) |
| C: 0.05 (EBIT TTM 296.1m / Avg Total Assets 5.47b) |
| D: -0.72 (Book Value of Equity -1.97b / Total Liabilities 2.74b) |
| Altman-Z'' Score: -1.31 = CCC |
What is the price of SBRA shares?
Over the past week, the price has changed by +4.55%, over one month by -0.99%, over three months by +1.69% and over the past year by +22.85%.
Is SBRA a buy, sell or hold?
- StrongBuy: 6
- Buy: 1
- Hold: 7
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SBRA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 21 | 10% |
| Analysts Target Price | 21 | 10% |
| ValueRay Target Price | 23.4 | 22.8% |
SBRA Fundamental Data Overview February 03, 2026
P/E Forward = 8.7108
P/S = 6.0948
P/B = 1.6347
P/EG = 3.15
Revenue TTM = 745.1m USD
EBIT TTM = 296.1m USD
EBITDA TTM = 474.0m USD
Long Term Debt = 2.59b USD (from longTermDebt, last quarter)
Short Term Debt = 1.26b USD (from shortTermDebt, last quarter)
Debt = 2.61b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.41b USD (from netDebt column, last quarter)
Enterprise Value = 6.97b USD (4.55b + Debt 2.61b - CCE 200.6m)
Interest Coverage Ratio = 2.65 (Ebit TTM 296.1m / Interest Expense TTM 111.6m)
EV/FCF = 20.42x (Enterprise Value 6.97b / FCF TTM 341.2m)
FCF Yield = 4.90% (FCF TTM 341.2m / Enterprise Value 6.97b)
FCF Margin = 45.79% (FCF TTM 341.2m / Revenue TTM 745.1m)
Net Margin = 23.50% (Net Income TTM 175.1m / Revenue TTM 745.1m)
Gross Margin = 66.38% ((Revenue TTM 745.1m - Cost of Revenue TTM 250.5m) / Revenue TTM)
Gross Margin QoQ = 63.35% (prev 67.70%)
Tobins Q-Ratio = 1.25 (Enterprise Value 6.97b / Total Assets 5.56b)
Interest Expense / Debt = 1.11% (Interest Expense 28.9m / Debt 2.61b)
Taxrate = 1.90% (436.0k / 23.0m)
NOPAT = 290.5m (EBIT 296.1m * (1 - 1.90%))
Current Ratio = 2.59 (Total Current Assets 320.7m / Total Current Liabilities 124.0m)
Debt / Equity = 0.93 (Debt 2.61b / totalStockholderEquity, last quarter 2.82b)
Debt / EBITDA = 5.09 (Net Debt 2.41b / EBITDA 474.0m)
Debt / FCF = 7.07 (Net Debt 2.41b / FCF TTM 341.2m)
Total Stockholder Equity = 2.74b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.20% (Net Income 175.1m / Total Assets 5.56b)
RoE = 6.38% (Net Income TTM 175.1m / Total Stockholder Equity 2.74b)
RoCE = 5.55% (EBIT 296.1m / Capital Employed (Equity 2.74b + L.T.Debt 2.59b))
RoIC = 5.57% (NOPAT 290.5m / Invested Capital 5.22b)
WACC = 4.35% (E(4.55b)/V(7.17b) * Re(6.23%) + D(2.61b)/V(7.17b) * Rd(1.11%) * (1-Tc(0.02)))
Discount Rate = 6.23% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 2.20%
[DCF Debug] Terminal Value 85.90% ; FCFF base≈328.4m ; Y1≈314.7m ; Y5≈305.9m
Fair Price DCF = 27.10 (EV 9.17b - Net Debt 2.41b = Equity 6.76b / Shares 249.3m; r=5.90% [WACC]; 5y FCF grow -5.55% → 2.90% )
EPS Correlation: 47.38 | EPS CAGR: -9.78% | SUE: -3.43 | # QB: 0
Revenue Correlation: 46.20 | Revenue CAGR: 104.4% | SUE: 0.27 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.17 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=0.75 | Chg30d=+0.000 | Revisions Net=-2 | Growth EPS=+9.0% | Growth Revenue=+11.7%